Scivision Biotech (TPE:1786) ROCE %: 12.26% (As of Dec. 2025)

What is Scivision Biotech ROCE %?

Scivision Biotech TPE:1786 -0.56% 80 ROCE % is 12.26% as of Dec. 2025. GuruFocus rates TPE:1786 with a GF Score™ of 80/100 and a GF Value™ of NT$115.23 (Possible Value Trap). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Scivision Biotech's annualized ROCE % for the quarter that ended in Dec. 2025 was 12.26%.

Scivision Biotech (TPE:1786) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Scivision Biotech ROCE % Related Terms

Scivision Biotech ROCE % Historical Data

* Premium members only.

The historical data trend for Scivision Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scivision Biotech ROCE % Chart

Scivision Biotech Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

6.89

9.46

10.95

14.74

8.55

Scivision Biotech Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
ROCE %	Get a 7-Day Free Trial															15.89	15.47	-6.80	13.85	12.26

80GF Score

Scivision Biotech Inc TPE:1786

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Scivision Biotech ROCE % Calculation

Scivision Biotech's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	192.969	/	( ( (2354.476 - 337.07)	+	(2669.579 - 174.648) )	/ 2 )
	=	192.969	/	( (2017.406	+	2494.931)	/ 2 )
	=	192.969	/	2256.1685
	=	8.55 %

Scivision Biotech's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2025 )		(Q: Sep. 2025 )		(Q: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2025 )		(Q: Sep. 2025 )		(Q: Dec. 2025 )
	=	301.956	/	( ( (2609.867 - 179.951)	+	(2669.579 - 174.648) )	/ 2 )
	=	301.956	/	( ( 2429.916	+	2494.931 )	/ 2 )
	=	301.956	/	2462.4235
	=	12.26 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 12.26% mean?

Scivision Biotech (TPE:1786) has a ROCE % of 12.26% as of Dec. 2025.

Is Scivision Biotech's ROCE % too high?

Scivision Biotech's current ROCE % is 12.26%. The Medical Devices & Instruments industry median ROCE % is 2.23. Scivision Biotech's value of 12.26% is 449.8% above this industry median. Overall, Scivision Biotech has a GF Score™ of 80/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.

How does Scivision Biotech's ROCE % compare to ISRG and BDX?

Scivision Biotech's ROCE % of 12.26% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.23. Scivision Biotech's value of 12.26% is 449.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.23, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Scivision Biotech's current ROCE % of 12.26% is 449.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scivision Biotech's current ROCE % is 12.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Scivision Biotech stock overvalued right now?

Based on GuruFocus' analysis, Scivision Biotech (TPE:1786) is currently considered Possible Value Trap. The stock's GF Value™ is NT$115.23, compared to a current price of NT$53.50 — trading 53.6% below its estimated fair value. The current ROCE % is 12.26% and 449.8% above the Medical Devices & Instruments industry median of 2.23. Scivision Biotech's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Scivision Biotech (TPE:1786), the current ROCE % is 12.26% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scivision Biotech (TPE:1786) Overvalued in 2026?

Based on GuruFocus' analysis, Scivision Biotech stock appears to be undervalued. The current stock price of NT$53.50 is trading 53.6% below its estimated GF Value™ of NT$115.23. GuruFocus considers Scivision Biotech to be Possible Value Trap.

Key valuation signals for TPE:1786:

ROCE %: 12.26%
GF Value™: NT$115.23 vs. price of NT$53.50 (53.6% below fair value)
GF Score™: 80/100 with 4 warning signs
Industry Position: 449.8% above the Medical Devices & Instruments median

No single metric tells the full story. See the TPE:1786 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scivision Biotech Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies TPE:1783 ROCO:6612 TPE:4737 TPE:1752 ROCO:1565 ROCO:5312 ROCO:4126 ROCO:6527 ROCO:4111 ROCO:4116 ISRG XPAR:EL TSE:7741 BDX XSWX:ALC MDLN RMD WST XSWX:STMN TSE:4543

Address No. 1, South 1st Road, Qianzhen District, Kaohsiung, TWN, 806

Website https://www.scivision.com.tw

Scivision Biotech Inc is engaged in the manufacturing and distribution of hyaluronic acid medical supplies in Taiwan. It offers medical devices, including absorbable adhesion barriers, dermal implants, synovial fluid supplements, and intravesical instillation.

80GF Score

Get the complete analysis for TPE:1786

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$53.50

Price

NT$115.23

GF Value

View TPE:1786 Analysis

See ROCE % data for all stocks →